Hay J W
Department of Clinical Pharmacy, Pharmaceutical Economics, and Policy, University of Southern California, Los Angeles, California, USA.
Clin Pharmacol Ther. 2008 Aug;84(2):197-200. doi: 10.1038/clpt.2008.124.
Pharmacotherapeutic decisions are increasingly constrained in all clinical settings by the costs of drug treatment and medical care. Some biotech therapies (e.g., Avastin, Cerzyme, Herceptin, Gleevec, Erbitux) can cost from $10,000 to more than $100,000 per treatment episode. In 1996 the average drug treatment cost for advanced colon cancer was $500, and the average patient survival was 11 months. In 2006 the average drug treatment cost for such patients was $250,000, and the average patient survival was 24 months.(1) It is apparent that we are quickly arriving at a situation in which the determinants of medical decision making are not simply the clinical risks and benefits of treatment options but also how these are balanced against the economic costs of therapy.
在所有临床环境中，药物治疗决策越来越受到药物治疗和医疗护理成本的限制。一些生物技术疗法（如阿瓦斯汀、思而赞、赫赛汀、格列卫、爱必妥）每次治疗费用可能从1万美元到超过10万美元不等。1996年，晚期结肠癌的平均药物治疗费用为500美元，患者平均生存期为11个月。2006年，此类患者的平均药物治疗费用为25万美元，患者平均生存期为24个月。（1）显然，我们很快就会面临这样一种情况：医疗决策的决定因素不仅是治疗方案的临床风险和益处，还包括这些因素如何与治疗的经济成本相平衡。
